GelStat Corporation (GSAC)

[greenlife]

PRESS RELEASES

GELSTAT CORPORATION REPORTS SECOND QUARTER RESULTS AND PROVIDES SHAREHOLDER UPDATE
Download PDF
THE COMPANY HAS A CURRENT BACKLOG IN EXCESS OF $500,000 TO BE COMPLETED AND DELIVERED BY YEAR-END 2014

PALM CITY, FL -- (Marketwired) -- 08/19/14 -- GelStat Corporation (PINKSHEETS: GSAC), a fully integrated consumer healthcare company engaged in the research, development, marketing and branding of innovative over-the-counter (OTC) consumer healthcare products addressing very large markets, reported results for the period ended June 30, 2014 and is updating shareholders on recent events.

Highlights for the Second Quarter 2014:

Reported revenue of $14,038 up 261% versus $3,880 over the same period in 2013 and up 136% from $5,942 in the 1st quarter ended 3/31/14. The revenue growth was attributable to increasing sales of GelStat Migraine primarily driven by small advertising tests designed to drive new customer acquisitions. While the revenue numbers themselves are insignificant, the trends and validation of marketing efforts are very meaningful. To review the financial reports for the period ended June 30, 2014 in detail visit: http://www.otcmarkets.com/financialReportViewer?symbol=GSAC&id=125149
Completed development and manufactured the initial inventory of Chews 2 Lose and began developing its direct-to-consumer marketing and branding collateral as well as secured a distribution agreement with Windmill Health Products. For more information visit: www.Chew2Lose.com
Completed the development and purchased the initial inventory of All Natural Speed.
Roger Cady, M.D. joins GelStat as its Chief Medical Advisor.
Larry Gershman, GelStat's CEO, said, "The second quarter of 2014 was another transformational quarter for GelStat as we increased sales of GelStat Migraine while preparing and purchasing inventory of Chews 2 Lose and All Natural Speed. Most importantly, we signed a definitive agreement to acquire Mastix Medica which we closed on July 7, 2014. This acquisition secured the future production of Chews 2 Lose, as well as brought significant revenue, resources and opportunities to GelStat."

Since the closing of the second quarter, the Company has achieved a number of significant milestones including:

Closed the acquisition of Mastix Medica completing our vertical integration strategy and providing a solid foothold in the rapidly growing high-CBD hemp oil products market.
Launched a new corporate website www.GelStat.com .
Robert Estey, COO of GelStat, said, "We have made great strides at Mastix Medica since the end of the second quarter. Several new products incorporating high-CBD industrial hemp oil have been developed by our in-house team and are ready for production and distribution to consumers in the near future. Purchase orders from five new customers have been received and are being produced and shipped over the next few months. Our product development project list is robust with a good combination of contract manufacturing customers and our own proprietary products."

Our primary objectives and outlook for the remainder of 2014:

Increasing the marketing efforts to secure additional contract manufacturing opportunities for Mastix Medica. Mastix has a solid pipeline of projects and purchase orders in excess of $500,000 to be completed by the end of 2014.
Building brand recognition and product placement through distribution agreements in select retailers for GelStat Migraine, Chews 2 Lose and All Natural Speed.
Developing additional high-CBD products leveraging Mastix Medica's proprietary methods to make functional gums and lozenges.
Collectively, GelStat forecasts revenue of $400,000 for the third quarter and $500,000 for the fourth quarter of 2014.
Make sure you are first to receive timely information on GelStat Corporation when it hits the newswire. Sign up for GelStat's email news alert system today at: http://ir.stockpr.com/gelstat2/email-alerts